PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ubstitute for form 1449A/B/PTO

JUN J 6 2006

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

to respond to a conection of milormation drives a keep control number.				
Complete if Known				
Application Number	10/559543			
Filing Date	December 2, 2005			
First Named Inventor	Russell Rother			
Art Unit	N/A			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	ALXN-P01-106			

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Document Number Publication Date		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY		
/R.S./	AA	6,491,916	12-10-2002	Bluestone et al.	
/R.S./	AB	2003/0100741	05-29-2003	Muller et al.	
/R.S./	AC	5,527,713	06-18-1996	Bolton et al.	
/R.S./	AD	6,352,694	03-05-2002	June et al.	
R.S./	AE	6,406,696	06-18-2002	Bluestone	
/R.S./	AF	6,143,297	11-07-2000	Bluestone	
/R.S./	AG	6,113,901	09-05-2000	Bluestone	
/R.S./	АН	5,929,212	07-27-1999	Jolliffe et al.	
/R.S./	ΑI	5,834,597	11-10-1998	Tso et al.	
/R.S./	AJ	5,316,763	05-31-1994	Ochoa et al.	
/R.S.	AK	5,821,337	10-13-1998	Carter et al.	

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear		
/R.S./	ВА	WO 02/069232	09-06-2002	Merck Patent GMBH et al.			
/R.S./	BB	WO 98/52976	11-26-1998	Biovation Limited et al.			
/R.S./	ВС	WO 91/09967	07-11-1991	Celltech Limited et al.			
/R.S./	BD	WO 00/34317	06-15-2000	Biovation Limited et al.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
/R.S./	CA	Jolliffe, "Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering," <i>International Reviews of Immunology,</i> 10:241-250 (1993).			
	CB	GenBank Accession No. D82081			
		ConBank Assession No. A22250	0000000000		
000000000000000000000000000000000000000	<u></u>	ConBank Associon No. A22261.	0000000000		
/R.S./	CE	Carpenter, et al. "Non-Fc Receptor Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells," <i>The Journal of Immunology</i> , 165:6205-6213(2000).			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner	(Panald Sahwadran)	Date	12/02/2008
Signature	/Honald Schwadron/	Considered	12/02/2000



PTO/SB/92 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/559543

Attorney Docket No.: ALXN-P01-106

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Signature

Jennifer Tardiff

Typed or printed name of person signing Certificate

(617) 951-7000

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pages)
IDS (Citation) by Applicant (20 References) (1 page)
Copies of references BA-BD and CA-CE
This postcard receipt